Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients Kappos L, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Wiendl H, Rose J, Greenberg S, Demirhan E, et al. ACTRIMS-ECTRIMS 2014. 09/12/2014. CommentRecommendBookmarkWatch